New Skin Barrier Product Reduces Costs for Ostomy Care
Clinical Trial Shows Improved Outcomes for Ceramide-Infused Ostomy Barriers
Article ID: 687659
Released: 9-Jan-2018 10:25 AM EST
Source Newsroom: Wolters Kluwer Health: Lippincott Williams and Wilkins
Newswise — January 9, 2018 – Ostomy patients using a new type of skin barrier product—infused with ceramides that play an essential role in the normal barrier function of the skin—experience lower costs of care, according to a randomized trial published in the Journal of Wound, Ostomy and Continence Nursing, the official journal of the Wound, Ostomy and Continence Nurses (WOCN®) Society. The journal is published by Wolters Kluwer.
An estimated 800,000 Americans live with an ostomy, with up to 80 percent experiencing high rates of peristomal skin complications (PSCs)—skin inflammation, injury, or damage occurring around the ostomy—that can lead to pain, reduce life satisfaction, and increase health care costs. The ceramide-infused skin barriers used in the study were designed to protect the skin around the ostomy and reduce moisture loss from damaged skin.
"The use of a ceramide-infused barrier significantly decreased cost and increased satisfaction with patient-reported outcomes compared to conventional skin barriers,” said Janice C. Colwell, MS, RN, CWOCN, FAAN, of University of Chicago Medicine, a principal author of the study report.
"Use of the ceramide-infused barrier significantly reduced stoma-related cost of care over a 12-week period," said Colwell. Adjusted average costs during this time were about $224 for patients using the new product versus $260 for the placebo group: a relative 14 percent reduction.
The cost savings included use of skin barriers and other ostomy care accessories, medications, emergency department and hospital visits, as well as "social costs" such as missed work or appointments.
The study enrolled 153 adult ostomy patients from 25 sites in the Unites States, Canada, and Europe. Patients were randomly assigned to use ceramide-infused or conventional (placebo) skin barrier products for 12 weeks. Costs of care, evidence of PSCs, and other outcomes were compared between groups. The study was sponsored by Hollister, Inc., manufacturer of the new skin barrier product.
Reflecting the high occurrence of complications among ostomy patients, the overall rate of PSCs was 47.7 percent. Patients using the ceramide-infused barriers were less likely to experience PSCs—40.5 percent versus 55.4 percent—but the difference was not statistically significant.
Seventy-five percent of patients using the ceramide-infused skin barrier said they were "very satisfied" with barrier performance, compared to 55 percent of those using conventional skin barriers. The ceramide-infused barriers were also rated higher for prevention of leakage and itching.
About Journal of WOCN
Journal of Wound, Ostomy and Continence Nursing is the official publication of the Wound Ostomy Continence Nurses Society (WOCN). This international journal provides continuing education for the entire scope of WOC nursing practice. Journal of WOCN is the authoritative resource devoted to the nursing care and management of patients with abdominal stomas, wounds, pressure injuries, fistulas, vascular ulcers, and incontinence. Original, peer-reviewed articles examine these topics in hospital, home and long-term care settings.
About the Wound Ostomy Continence Nurses Society™
The Wound, Ostomy and Continence Nurses Society™ (WOCN®) a professional nursing society that supports its members by promoting educational, clinical, and research opportunities to advance the practice and guide the delivery of expert health care to individuals with wounds, ostomies, and incontinence.
About Wolters Kluwer
Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2016 annual revenues of €4.3 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and the organization, visit http://www.wolterskluwer.com/, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.